Home Cart Sign in  
Chemical Structure| 316173-57-6 Chemical Structure| 316173-57-6

Structure of SCH442416
CAS No.: 316173-57-6

Chemical Structure| 316173-57-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SCH-442416 is a selective adenosine A2A receptor antagonist. SCH-442416 binds to human and rat A2A receptors with high affinity (Ki values are 0.048 and 0.5 nM respectively). It displays > 23000-fold selectivity for hA2A over hA1 in vitro with minimal affinity for hA2B and hA3 receptors (IC50 > 10 μM).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SCH442416

CAS No. :316173-57-6
Formula : C20H19N7O2
M.W : 389.41
SMILES Code : NC1=NC(N(CCCC2=CC=C(OC)C=C2)N=C3)=C3C4=NC(C5=CC=CO5)=NN14
MDL No. :MFCD08703126
InChI Key :AEULVFLPCJOBCE-UHFFFAOYSA-N
Pubchem ID :10668061

Safety of SCH442416

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of SCH442416

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Müller cells 100 nM 2 weeks SCH442416 significantly increased Kir4.1 and TASK-1 protein expressions and enhanced inward potassium currents in Müller cells Sci Rep. 2015 Jun 11;5:11294
Human subcutaneous fibroblasts (HSCF) 10 nM 28 days SCH442416 blocked the A2A receptor, preventing the pro-fibrotic effects of AMP and CGS21680C on collagen production Cells. 2020 Mar 7;9(3):651
HEK-293T cells 10 µM 5 minutes To evaluate the inhibitory effect of MRS7145 on A2AR-mediated cAMP accumulation, results showed that MRS7145 significantly inhibited CGS21680-induced cAMP accumulation under light conditions J Control Release. 2018 Aug 10;283:135-142
HEK-293T cells 1 µM 5 minutes To evaluate the blocking effect of MRS7145 on A2AR ligand binding, results showed that MRS7145 effectively blocked APEC647 binding to A2AR under light conditions J Control Release. 2018 Aug 10;283:135-142
MDA-MB-231 breast cancer cells 1 µM 72 hours Evaluate the effect of A2AR antagonist on extracellular vesicle production, results showed SCH442416 significantly decreased exosome production. Purinergic Signal. 2020 Jun;16(2):231-240
Mel526 metastatic melanoma cells 1 µM 72 hours Evaluate the effect of A2AR antagonist on extracellular vesicle production, results showed SCH442416 significantly decreased exosome production. Purinergic Signal. 2020 Jun;16(2):231-240
U251 glioblastoma cells 1 µM 72 hours Evaluate the effect of A2AR antagonist on extracellular vesicle production, results showed SCH442416 significantly decreased exosome production. Purinergic Signal. 2020 Jun;16(2):231-240
UMSCC47 cells 1 µM 72 hours Evaluate the effect of A2AR antagonist on extracellular vesicle production, results showed SCH442416 stimulated exosome production under metabolic stress or cisplatin treatment. Purinergic Signal. 2020 Jun;16(2):231-240
CHO cells 20 nM at least 2 hours To assess whether CBD interacts with the orthosteric site of the A2A receptor. Results showed that CBD was unable to significantly compete for the binding of the labeled antagonist to the receptor. Int J Mol Sci. 2023 Dec 15;24(24):17500
Sheep brain striatum membranes 0.1 nM to 50 μM To study the role of SCH442416 as an A2AR antagonist in competitive binding experiments, the results showed that SCH442416 could produce bell-shaped competition curves, indicating the existence of a ligand-competitor allosteric interaction. Pharmacol Res. 2019 Jan;139:337-347

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rat Rat caudate putamen brain slices Perfusion 1 µM 30 minutes To test the role of A2A receptors in dopamine release modulation, results showed SCH442416 did not affect dopamine release J Neurochem. 2015 Jan;132(1):51-60
Rats 6-hydroxydopamine (6-OHDA) hemi-parkinsonian rat model Micro-pressure administration 1 µM Single administration SCH442416 significantly increased the spontaneous firing rate of pallidal neurons, indicating that endogenous adenosine modulates the activity of pallidal neurons through adenosine A 2A receptors Front Physiol. 2017 Nov 7;8:897
Sprague Dawley rats Chronic ocular hypertension (COH) model Intravitreal injection 100 nM Single injection, lasting 2 weeks SCH442416 up-regulated Müller cell Kir4.1, TASK-1, GS and GLAST expressions and enhanced inward potassium currents, while increasing retinal ganglion cell (RGC) count Sci Rep. 2015 Jun 11;5:11294
Mice Unilateral 6-hydroxydopamine (6-OHDA)-lesioned Parkinson’s disease model Intraperitoneal injection 3 mg/kg Single administration, irradiation for 20 minutes To evaluate the enhancing effect of MRS7145 on L-DOPA-induced contralateral rotations under light conditions, results showed that MRS7145 significantly potentiated the effect of L-DOPA under light conditions J Control Release. 2018 Aug 10;283:135-142
Mice (C57BL/6) Wild-type and CB1 receptor knockout mice Intraperitoneal 3 mg/kg Single injection, monitored for 30 min SCH442416 robustly increased locomotor activity, an effect attenuated by CB1 receptor blockade or knockout J Neurosci. 2010 Feb 10;30(6):2160-4
Rats Bilateral common carotid artery occlusion (BCCAO) model Intraperitoneal injection 3 mg/kg Administered before BCCAO To evaluate the effects of A2A receptors on rapid adenosine and oxygen dynamics during I/R. SCH 442416 eliminated the increase in adenosine and oxygen events caused by I/R. ACS Chem Neurosci. 2019 Apr 17;10(4):1941-1949
Rats Anesthetized rats Intraperitoneal injection 3 mg/kg Single dose, observed for 2 hours SCH442416 significantly decreased the number of adenosine and oxygen transient events and increased the time interval between each transient release. J Neurochem. 2017 Jan;140(1):13-23

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00531193 Healthy Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT02764892 Parkinson's Disease Phase 1 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.84mL

2.57mL

1.28mL

25.68mL

5.14mL

2.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories